It is well established that p53 mutation confers resistance of tumor cells to a wide range of chemotherapeutic agents [38], and several studies have demonstrated increased chemoresistance in tumors expressing gain-of-function p53 mutants compared to those lacking p53 altogether [17,20,21,25,29]. The gene discussed is TP53; the disease is neoplasm.